Anbio Biotechnology
Ticker(s):
NNNN
Country:
Sector & Industry:
Business Overview
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Contact & Other Information
Number of Employees:
Website:
,
,
Anbio Biotechnology announced the closing of its initial public offering of 1,600,000 Class A ordinary shares at a price of $5.00 per share.